On October 23, reports surfaced indicating that the expansive cancer pathology-gene model, DeepGEM, has been successfully implemented at KingMed Diagnostics. In a collaborative effort, KingMed Diagnostics is set to join forces with Tencent and the First Affiliated Hospital of Guangzhou Medical University. Their shared mission is to develop a cutting-edge, multi-modal pathology-gene model. This initiative is driven by the ambition to extend the reach of precise, timely, and accessible gene mutation prediction technology, ultimately benefiting a broader spectrum of cancer patients.
